Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT02365714 Terminated - Breast Cancer Clinical Trials

CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)

CK-SAPBI
Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects and cosmetic results.

NCT ID: NCT02365662 Terminated - Clinical trials for Non-small Cell Lung Cancer

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Start date: January 9, 2015
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors likely to exhibit elevated levels of Epidermal Growth Factor Receptor (EGFR).

NCT ID: NCT02345330 Terminated - Clinical trials for Head and Neck Squamous Cell Carcinoma

Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)

Start date: May 21, 2015
Phase: Phase 2
Study type: Interventional

This study will assess the safety and effectiveness of ImmunoPulse IL-12® in treatment-refractory metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC). ImmunPulseIL12® is the combination of intrtumoral interleukin-12 gene (also known as tavokinogene telseplasmid [tavo]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid [DNA] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS). Intratumoral tavo is a gene therapy approach to directly induce a pro-inflammatory response within a tumor to initiate and/or enhance anti-tumor immunity.

NCT ID: NCT02338570 Terminated - Clinical trials for Renal Cell Carcinoma

Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)

ORCHIDEE
Start date: July 2015
Phase: Phase 4
Study type: Interventional

Evaluation of unfavourable outcome-related factors in patients affected by renal cell cancer in treatment with everolimus and previously treated with a Vascular endothelial growth factor (VEGF) inhibitor (i.e. sunitinib, sorafenib,pazopanib, or bevacizumab+interferon)

NCT ID: NCT02334319 Terminated - Clinical trials for Stage IVA Oropharyngeal Squamous Cell Carcinoma

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies how well ganetespib works before surgery in treating patients with stage I-IVA squamous cell carcinoma of the head and neck that can be removed by surgery. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tissue in the laboratory from patients receiving ganetespib may help doctors learn more about the effects of ganetespib on cells. It may also help doctors understand how well patients respond to treatment.

NCT ID: NCT02331875 Terminated - Clinical trials for Squamous Cell Carcinoma of the Oral Cavity

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this open label Phase Ib/II trial is to evaluate the clinical and pharmacological activity of IPH2201 as a single-agent in treatment-naïve pre-operative patients with operable Squamous Cell Carcinoma of the Oral Cavity . 43 patients are planned to be enrolled. The first 6 patients will receive IPH2201 at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4. Standard loco-regional treatment with surgery followed by adjuvant therapy will be initiated after the last administration of IPH2201.

NCT ID: NCT02325349 Terminated - Clinical trials for Advanced Head and Neck Carcinoma

PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents

MLAPOCHI
Start date: March 20, 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this Phase II study is to evaluate the use of labelled RGD ligand in PET/CT to predict and/or to early assess the efficacy of chemotherapy including an agent with antiangiogenic effect. The predictive value of this approach will be determined by independent assessors on basis of data at the end of the treatment: RECIST 1.1 criteria for CT or MRI, PERCIST criteria for FDG PET/CT, clinical, endoscopic and histological findings.

NCT ID: NCT02323906 Terminated - Clinical trials for Carcinoma, Hepatocellular

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

Start date: January 16, 2015
Phase: Phase 1
Study type: Interventional

CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC. The dose escalation phase of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part of the study using the optimal combination dose regimen.

NCT ID: NCT02323360 Terminated - Clinical trials for Hepatocellular Carcinoma

A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC

Start date: November 2014
Phase: N/A
Study type: Interventional

The trial is a multicentre, prospective, randomised controlled, unblinded, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of inoperable HCC treated with a TAE/TACE incomplete cycle.

NCT ID: NCT02319200 Terminated - Clinical trials for Hepatocellular Carcinoma

Primary Prevention Hepatocellular Carcinoma by Metformin

METFOVIR
Start date: June 2015
Phase: Phase 3
Study type: Interventional

Metformin treatment during 36 months could be associated with decreased risk of HCC occurrence and liver related death in patients with compensated HCV cirrhosis and insulinoresistance. This study is an ancillary of the observational study from the CIRVIR cohort in which more than 1200 patients with compensated HCV cirrhosis are currently included. participating centers : 26